Chronic viral HBeAg-negative hepatitis B: Epidemiological, clinical and biochemical characteristics in an outpatient descriptive cohort in Burkina Faso

Chronic viral HBeAg-negative hepatitis B: Epidemiological, clinical and biochemical characteristics in an outpatient descriptive cohort in Burkina Faso

Introduction: Our study aimed to describe epidemiological and diagnostic features in an outpatient's cohort with chronic HBeAg-negative hepatitis B. Patients and methods: A cross-sectional descriptive study with a retrospective data collection was implemented from January 2004 to April 2016 in...

Full description

Bibliographic Details
Main Authors:	Eric Nagaonlé Somé, Alice Nanelin Guingané, Issaka Zongo, Daouda Sané, Koiné Maxime Drabo, Roger Sombié
Format:	Article
Language:	English
Published:	Elsevier 2021-07-01
Series:	Clinical Epidemiology and Global Health
Subjects:	Viral hepatitis Hepatitis B virus Hepatitis B e Antigen Sub saharan Africa
Online Access:	http://www.sciencedirect.com/science/article/pii/S221339842100107X

Similar Items

The hepatocellular carcinoma's risk factors among in-hospital patients at the university-teaching hospital Yalgado Ouédraogo in Ouagadougou, Burkina Faso: A case-control study
by: Eric Nagaonlé Somé, et al.
Published: (2022-01-01)

Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
by: Byung-Cheol Song, et al.
Published: (2014-12-01)

Relation of hepatitis B core antigen expression with histological activity, serum HBeAg, and HBV DNA levels
by: Aysegul Sari, et al.
Published: (2011-01-01)

Seroconversion of hepatitis B envelope antigen (HBeAg) by entecavir in a child with chronic hepatitis B
by: Mohammed Y Hasosah, et al.
Published: (2012-01-01)

Mathematical investigation of HBeAg seroclearance
by: Sarah Kadelka, et al.
Published: (2019-08-01)

HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
by: Cheng-Yuan Peng, et al.
Published: (2015-04-01)

Evaluation of the Diagnostic Performances of the SD-Bioline<sup>®</sup>HBeAg Rapid Test Used Routinely for the Management of HBV-Infected Individuals in Burkina Faso
by: Abdoulaye Dera, et al.
Published: (2023-10-01)

Outcomes of hepatitis B immunoglobulin and hepatitis B vaccination in high-risk newborns born to HBeAg-positive mothers
by: Chen-Hsuan Wu, et al.
Published: (2022-10-01)

Quantitative HBsAg versus HBV DNA in Predicting Significant Hepatitis Activity of HBeAg-Positive Chronic HBV Infection
by: Zhanqing Zhang, et al.
Published: (2021-11-01)

Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?
by: Ho Soo Chun, et al.
Published: (2021-07-01)

Quantitative HBsAg levels do not identify hepatic fibrosis in HBeAg-negative chronic hepatitis B patients
by: Fatima A Ahmed, et al.
Published: (2019-01-01)

Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs
by: Cai S, et al.
Published: (2018-04-01)

Is the function of the HBeAg really unknown?
by: David R. Milich
Published: (2019-09-01)

A novel nomogram for predicting HBeAg seroclearance in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues
by: Yan Gu, et al.
Published: (2024-01-01)

The Complex Role of HBeAg and Its Precursors in the Pathway to Hepatocellular Carcinoma
by: Kiyasha Padarath, et al.
Published: (2023-03-01)

Quantitative HBsAg and Qualitative HBeAg Predicts Intrauterine Placental Infection and Umbilical Blood Cord in Pregnant Women
by: Erry Gumilar Dachlan, et al.
Published: (2020-10-01)

Immunogenicity and Antiviral Response of Therapeutic Hepatitis B Vaccination in a Mouse Model of HBeAg-Negative, Persistent HBV Infection
by: Anna D. Kosinska, et al.
Published: (2021-07-01)

HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients
by: Guangjun Song, et al.
Published: (2023-11-01)

Possible immunochemical pattern of anti-HCV, HBeAg, HBsAg HBeAb, and HIV-1 p24 in newly infected Mycobacterium pulmonary tuberculosis patients
by: Mathew Folaranmi Olaniyan, et al.
Published: (2019-01-01)

Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B
by: Minghui Li, et al.
Published: (2022-09-01)

Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients
by: Jong Hwa Na, et al.
Published: (2021-06-01)

MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients
by: Chen X, et al.
Published: (2022-03-01)

Characteristics of treatment naive chronic hepatitis B in Bangladesh: Younger populations are more affected; HBeAg-negatives are more advanced
by: Alam Shahinul, et al.
Published: (2008-01-01)

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
by: Young Jip Kim, et al.
Published: (2013-09-01)

Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA
by: Jian Wang, et al.
Published: (2024-12-01)

Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients
by: Minghui Li, et al.
Published: (2022-05-01)

Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks
by: Xiaomei Wang, et al.
Published: (2020-10-01)

Comparison of antibody response to hepatitis B vaccination in infants with positive or negative maternal hepatitis B e antigen (HBeAg) in cord blood: implication for the role of HBeAg as an immunotolerogen
by: Hongyu Huang, et al.
Published: (2019-09-01)

Comparison of evolutionary patterns of different HBeAg status in HBV genotype B and C
by: Cai Ying, et al.
Published: (2015-12-01)

The Circulating miRNA Profile of Chronic Hepatitis D and B Patients Is Comparable but Differs from That of Individuals with HBeAg-Negative HBV Infection
by: Daniela Cavallone, et al.
Published: (2023-11-01)

Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase: a retrospective study
by: Sufang Wei, et al.
Published: (2022-08-01)

The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions
by: Ott Jördis J, et al.
Published: (2012-06-01)

HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers
by: Luisa Roade, et al.
Published: (2023-10-01)

Expression of Functional Molecule on Plasmacytoid Dendritic Cells Is Associated With HBsAg Loss in HBeAg-Positive Patients During PEG-IFN α-2a Treatment
by: Weihua Cao, et al.
Published: (2022-05-01)

The changing epidemiology of hepatitis B and C infections in Nanoro, rural Burkina Faso: a random sampling survey
by: Moussa Lingani, et al.
Published: (2020-01-01)

What is the reason of elevated alanine aminotransferase level in HBeAg negative patients with low viremia: NAFLD or chronic hepatitis?
by: Kadir Demir, et al.
Published: (2007-04-01)

Predictive Factors for Sustained Remission after Discontinuation of Antiviral Therapy in Patients with HBeAg-positive Chronic Hepatitis B
by: Baek Gyu Jun, et al.
Published: (2016-01-01)

Hepatitis B virus infection and HBeAg positivity among pregnant women in South West Uganda
by: Naome Mugabiirwe, et al.
Published: (2022-08-01)

Characterization of HBeAg-negative chronic hepatitis B in western Brazilian Amazonia
by: Flamir da Silva Victoria, et al.

The effects of prolonged Lamivudine administration as a sole treatment following the combination therapy of Interferon Alpha and Lamivudine in children for HBeAg (+) chronic hepatitis B
by: Sezin Asik Akman,1 Sabriye Cokceken Okcu,2 Sumer Sutcuoglu.2
Published: (2007-10-01)